Puma Biotechnology (PBYI) Competitors $2.84 +0.10 (+3.65%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PBYI vs. RAPT, MRNS, URGN, AKBA, CRVS, SANA, GLUE, PRTC, MREO, and TERNShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include RAPT Therapeutics (RAPT), Marinus Pharmaceuticals (MRNS), UroGen Pharma (URGN), Akebia Therapeutics (AKBA), Corvus Pharmaceuticals (CRVS), Sana Biotechnology (SANA), Monte Rosa Therapeutics (GLUE), PureTech Health (PRTC), Mereo BioPharma Group (MREO), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. RAPT Therapeutics Marinus Pharmaceuticals UroGen Pharma Akebia Therapeutics Corvus Pharmaceuticals Sana Biotechnology Monte Rosa Therapeutics PureTech Health Mereo BioPharma Group Terns Pharmaceuticals RAPT Therapeutics (NASDAQ:RAPT) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Do institutionals and insiders believe in RAPT or PBYI? 99.1% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 6.6% of RAPT Therapeutics shares are held by company insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is RAPT or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to RAPT Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat RAPT Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RAPT TherapeuticsN/A -89.10% -76.13% Puma Biotechnology 9.56%41.60%10.71% Do analysts recommend RAPT or PBYI? RAPT Therapeutics presently has a consensus price target of $9.50, suggesting a potential upside of 787.85%. Puma Biotechnology has a consensus price target of $7.00, suggesting a potential upside of 146.48%. Given RAPT Therapeutics' higher probable upside, equities analysts clearly believe RAPT Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RAPT Therapeutics 1 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.08Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, RAPT or PBYI? Puma Biotechnology has higher revenue and earnings than RAPT Therapeutics. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRAPT Therapeutics$1.53M24.45-$116.80M-$2.77-0.39Puma Biotechnology$235.60M0.59$21.59M$0.485.92 Does the media refer more to RAPT or PBYI? In the previous week, RAPT Therapeutics had 12 more articles in the media than Puma Biotechnology. MarketBeat recorded 14 mentions for RAPT Therapeutics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.67 beat RAPT Therapeutics' score of 0.52 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RAPT Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community prefer RAPT or PBYI? Puma Biotechnology received 459 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. Likewise, 66.99% of users gave Puma Biotechnology an outperform vote while only 63.12% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformRAPT TherapeuticsOutperform Votes8963.12% Underperform Votes5236.88% Puma BiotechnologyOutperform Votes54866.99% Underperform Votes27033.01% Which has more risk & volatility, RAPT or PBYI? RAPT Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. SummaryPuma Biotechnology beats RAPT Therapeutics on 13 of the 18 factors compared between the two stocks. Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.42M$6.40B$5.01B$8.81BDividend YieldN/A8.11%5.18%4.07%P/E Ratio5.9210.06132.0317.50Price / Sales0.59318.831,202.2589.00Price / Cash3.4822.1633.2732.51Price / Book2.545.454.684.68Net Income$21.59M$152.96M$118.21M$225.43M7 Day Performance-4.38%-4.28%-2.36%-2.06%1 Month Performance-1.39%-8.65%-3.97%0.03%1 Year Performance-26.99%28.57%29.71%24.47% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology4.4109 of 5 stars$2.84+3.6%$7.00+146.5%-27.0%$134.50M$235.60M5.92185Analyst ForecastPositive NewsRAPTRAPT Therapeutics4.5981 of 5 stars$1.07flat$9.50+787.9%-92.3%$37.40M$1.53M0.0080MRNSMarinus Pharmaceuticals4.5957 of 5 stars$0.31flat$4.79+1,448.8%-95.0%$17.05M$30.99M-0.13110Analyst ForecastAnalyst RevisionURGNUroGen Pharma3.78 of 5 stars$11.45+2.6%$48.38+322.5%-7.9%$261.74M$82.71M0.00200AKBAAkebia Therapeutics4.0169 of 5 stars$1.79-1.6%$5.75+221.2%+75.5%$390.54M$194.62M-7.78167CRVSCorvus Pharmaceuticals2.8214 of 5 stars$8.24-1.9%$12.83+55.7%+449.3%$529.50MN/A-8.7130Analyst RevisionSANASana Biotechnology2.2165 of 5 stars$2.53+7.2%$13.50+433.6%-41.2%$526.91MN/A0.00328GLUEMonte Rosa Therapeutics2.9578 of 5 stars$8.36+0.6%$16.00+91.4%+157.2%$513.61M$14.98M-4.5790PRTCPureTech Health2.2347 of 5 stars$21.70+2.1%$45.00+107.4%+0.9%$508.96M$3.33M0.00100News CoveragePositive NewsMREOMereo BioPharma Group2.9648 of 5 stars$3.58+2.6%$7.50+109.5%+63.5%$502.13M$10M0.0040Analyst RevisionTERNTerns Pharmaceuticals4.3236 of 5 stars$5.60-5.2%$27.25+386.6%+49.3%$501.99M$1M0.0040 Related Companies and Tools Related Companies RAPT Therapeutics Competitors Marinus Pharmaceuticals Competitors UroGen Pharma Competitors Akebia Therapeutics Competitors Corvus Pharmaceuticals Competitors Sana Biotechnology Competitors Monte Rosa Therapeutics Competitors PureTech Health Competitors Mereo BioPharma Group Competitors Terns Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PBYI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
